Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2003 1
2004 1
2005 1
2006 1
2007 6
2008 5
2009 4
2010 1
2011 2
2012 2
2013 3
2014 3
2015 6
2016 1
2017 1
2018 6
2019 2
2020 2
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

47 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Genotype and risk of major bleeding during warfarin treatment.
Kawai VK, Cunningham A, Vear SI, Van Driest SL, Oginni A, Xu H, Jiang M, Li C, Denny JC, Shaffer C, Bowton E, Gage BF, Ray WA, Roden DM, Stein CM. Kawai VK, et al. Pharmacogenomics. 2014 Dec;15(16):1973-83. doi: 10.2217/pgs.14.153. Pharmacogenomics. 2014. PMID: 25521356 Free PMC article.
AIM: To determine whether genetic variants associated with warfarin dose variability were associated with increased risk of major bleeding during warfarin therapy. ...CONCLUSION: The CYP2C9*3 allele may double the risk of major
AIM: To determine whether genetic variants associated with warfarin dose variability were associated with increased risk of …
Incremental Value of Genotype Bins over the HAS-BLED Score for the Prediction of Bleeding Risk in Warfarin-Treated Patients with Atrial Fibrillation.
Liu J, Wang G, Qin L, Wu Y, Zou Y, Wang X, Wang Z, Wang Y, Zhang S, Zhang Y, Yin T. Liu J, et al. Cardiol Res Pract. 2021 Nov 23;2021:9030005. doi: 10.1155/2021/9030005. eCollection 2021. Cardiol Res Pract. 2021. PMID: 34858664 Free PMC article.
BACKGROUND: This study aimed to analyse the role of the HAS-BLED score with the addition of genotype bins for bleeding risk prediction in warfarin-treated patients with atrial fibrillation (AF). ...With the addition of genotype bins, the perform …
BACKGROUND: This study aimed to analyse the role of the HAS-BLED score with the addition of genotype bins for bleeding risk
The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.
Tomek A, Maťoška V, Kolářová T, Neumann J, Srámek M, Sarbochová I, Táborský L, Bojar M, Goetz P, Serebruany VL. Tomek A, et al. Cardiology. 2013;125(3):182-91. doi: 10.1159/000350407. Epub 2013 Jun 12. Cardiology. 2013. PMID: 23774101
BACKGROUND: Warfarin is commonly used for the treatment and prevention of arterial and venous thromboembolism but its use is hindered by the risk of bleeding. The main reason for this risk is a narrow therapeutic index and a wide response variab …
BACKGROUND: Warfarin is commonly used for the treatment and prevention of arterial and venous thromboembolism but its use is h …
Genotype-guided dosing versus conventional dosing of warfarin: A meta-analysis of 15 randomized controlled trials.
Yang T, Zhou Y, Chen C, Lu M, Ma L, Cui Y. Yang T, et al. J Clin Pharm Ther. 2019 Apr;44(2):197-208. doi: 10.1111/jcpt.12782. Epub 2018 Dec 28. J Clin Pharm Ther. 2019. PMID: 30593674 Review.
WHAT IS KNOWN AND OBJECTIVE: Genotype-guided warfarin dosing algorithm is designed to predict the initial and stable dose of warfarin. ...Risk of bias of eligible RCTs was assessed with the Cochrane Collaboration's tool. ...
WHAT IS KNOWN AND OBJECTIVE: Genotype-guided warfarin dosing algorithm is designed to predict the initial and stable dose of …
Genotype-guided warfarin therapy: Still of only questionable value two decades on.
Shah RR. Shah RR. J Clin Pharm Ther. 2020 Jun;45(3):547-560. doi: 10.1111/jcpt.13127. Epub 2020 Mar 13. J Clin Pharm Ther. 2020. PMID: 32168383
METHODS: Major widely-cited warfarin pharmacogenetic studies as well as recent meta-analyses were identified and a critical analysis of these was undertaken to identify factors that may account for poor clinical implementation of pre-treatment genotyping
METHODS: Major widely-cited warfarin pharmacogenetic studies as well as recent meta-analyses were identified and a critical an …
Genotype-guided drug prescribing: a systematic review and meta-analysis of randomized control trials.
Goulding R, Dawes D, Price M, Wilkie S, Dawes M. Goulding R, et al. Br J Clin Pharmacol. 2015 Oct;80(4):868-77. doi: 10.1111/bcp.12475. Epub 2015 Jul 22. Br J Clin Pharmacol. 2015. PMID: 25060532 Free PMC article. Review.
Eight studies had statistically significant results for their primary outcome in favour of genotype-guided prescribing. Nine studies evaluated genotype-guided warfarin dosing. ...There was a statistically significant reduction in numbers of warfarin-re …
Eight studies had statistically significant results for their primary outcome in favour of genotype-guided prescribing. Nine studies …
Role of pharmacogenomics in the management of traditional and novel oral anticoagulants.
Cavallari LH, Shin J, Perera MA. Cavallari LH, et al. Pharmacotherapy. 2011 Dec;31(12):1192-207. doi: 10.1592/phco.31.12.1192. Pharmacotherapy. 2011. PMID: 22122181 Free PMC article. Review.
Numerous studies have demonstrated significant contributions of these genes to warfarin dose requirements. The CYP2C9 gene has also been associated with bleeding risk with warfarin. ...Clinical trials are ongoing to determine the clinical utility and c …
Numerous studies have demonstrated significant contributions of these genes to warfarin dose requirements. The CYP2C9 gene has also b …
Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients.
Palareti G, Cosmi B. Palareti G, et al. Thromb Haemost. 2009 Aug;102(2):268-78. doi: 10.1160/TH08-11-0730. Thromb Haemost. 2009. PMID: 19652877 Review.
Bleeding is the most important complication of VKAs and a major concern for both physicians and patients. ...This review analyses the treatment- and person-associated risk factors for bleeding during VKAs and their combination in clinical predic
Bleeding is the most important complication of VKAs and a major concern for both physicians and patients. ...This review analy
Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study.
Perreault S, Shahabi P, Côté R, Dumas S, Rouleau-Mailloux É, Feroz Zada Y, Provost S, Mongrain I, Dorais M, Huynh T, Kouz S, Diaz A, Blostein M, de Denus S, Turgeon J, Ginsberg J, Lelorier J, Lalonde L, Busque L, Kassis J, Talajic M, Tardif JC, Dubé MP. Perreault S, et al. Clin Cardiol. 2018 May;41(5):576-585. doi: 10.1002/clc.22948. Epub 2018 May 15. Clin Cardiol. 2018. PMID: 29542828 Free PMC article.
Genetic material was collected, and genotyping of CYP2C9 and VKORC1 genes was conducted. Measured outcomes included the percentage of time patients spent within therapeutic range, anticoagulation control, warfarin dose, bleeding, and thromboembolic events. .. …
Genetic material was collected, and genotyping of CYP2C9 and VKORC1 genes was conducted. Measured outcomes included the percentage of …
Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis.
Yang J, Chen Y, Li X, Wei X, Chen X, Zhang L, Zhang Y, Xu Q, Wang H, Li Y, Lu C, Chen W, Zeng C, Yin T. Yang J, et al. Int J Cardiol. 2013 Oct 9;168(4):4234-43. doi: 10.1016/j.ijcard.2013.07.151. Epub 2013 Aug 7. Int J Cardiol. 2013. PMID: 23932037 Review.
BACKGROUND: The main challenge for warfarin anticoagulation is the risk for hemorrhagic complications. ...CYP2C9*3 is the main genetic risk factor for warfarin hemorrhagic complications....
BACKGROUND: The main challenge for warfarin anticoagulation is the risk for hemorrhagic complications. ...CYP2C9*3 is the main …
47 results